Hormone Therapy Recommendations for Adenomyosis
For adenomyosis, progestins—particularly dienogest (2 mg daily), the levonorgestrel-releasing intrauterine system (LNG-IUS 52 mg), or oral progestins—are the recommended first-line hormonal treatments for long-term symptom management, with treatment selection guided by whether heavy menstrual bleeding or pain predominates. 1
Treatment Selection Algorithm
For Heavy Menstrual Bleeding (HMB) Predominant Disease:
- LNG-IUS (52 mg) is highly effective for bleeding control and can be maintained long-term with low discontinuation rates (15% due to side effects) 2
- Dienogest (2 mg daily) significantly reduces HMB but has higher treatment switching rates (49% after first year) due to side effects or contraception needs 2
- Drospirenone (4 mg) or desogestrel (75 mcg) are alternatives, though desogestrel shows reduced long-term efficacy 2
For Pain-Predominant Disease (Dysmenorrhea, Dyspareunia, Chronic Pelvic Pain):
- Dienogest (2 mg daily) demonstrates superior long-term efficacy with favorable side-effect profiles for pain symptoms 3
- Combined oral contraceptives (COCs) are effective for dysmenorrhea reduction but show limited benefit for other symptoms 4, 3
- Depot medroxyprogesterone acetate is effective compared to placebo and may be equivalent to more costly regimens 5
For Severe or Refractory Disease:
- GnRH agonists (minimum 3 months) or GnRH antagonists are reserved for second-line treatment due to hypoestrogenic side effects 5, 1
- When GnRH agonist therapy is continued, add-back therapy reduces or eliminates bone mineral loss without reducing pain relief efficacy 5
- Ultra-long GnRH agonist protocols (extended suppression) may improve outcomes in fertility-preserving contexts, particularly before embryo transfer 6
Evidence Quality and Nuances
The 2023 Canadian guideline 1 provides the most recent comprehensive framework, though it acknowledges limited high-quality randomized controlled trial data specifically for adenomyosis. The distinction from endometriosis is critical: while adenomyosis and endometriosis share hormonal dependency and similar treatment targets (ectopic endometrium), they have distinct epidemiological features 7.
Key strength of recent evidence: The 2025 prospective study 2 tracking 140 patients over 3+ years provides the most robust long-term data on progestin efficacy, showing dienogest and LNG-IUS maintain effectiveness but with notable switching rates requiring treatment flexibility.
Common Pitfalls to Avoid
- Do not assume medical therapy eradicates lesions—hormonal treatments reduce lesion size and symptoms but do not eliminate adenomyosis 5, 8
- Avoid uniform treatment approaches—MRI-based lesion localization (diffuse vs. focal) and symptom phenotype (bleeding vs. pain dominant) should guide selection 9
- Consider fertility intentions upfront—time-limited interventions are central in fertility-preserving management, with GnRH agonist pretreatment potentially improving ART outcomes 6
- Plan for treatment switching—nearly half of dienogest patients require alternative therapy after one year, so establish flexible sequential strategies 2
Treatment Duration and Maintenance
Long-term management is required given adenomyosis's chronic nature 2. Progestins can be maintained for years with appropriate monitoring, while GnRH agonists should be limited due to bone density concerns unless add-back therapy is used 5. The flexibility to switch between different progestins or routes of administration (oral vs. intrauterine) optimizes long-term outcomes 2.